EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer
Umberto Malapelle(Federico II University Hospital), Giancarlo Troncone(Federico II University Hospital), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Luisella Righi(Ospedale San Luigi Gonzaga), Caterina De Luca(University of Naples Federico II), Simona Vatrano(European Gravitational Observatory), Roberta Sgariglia(University of Naples Federico II), Stefania Russo(National Center for Oncological Hadrontherapy), Élisa Gobbini(Institut Curie), Danilo Rocco, Claudio Bellevicine(University of Naples Federico II), Livia De Pietro
Cited by 7
Related Papers
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180
Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer
|Expert Review of Molecular Diagnostics|2017|171